{
  "version": "1.2.0",
  "chapters": [
    {
      "startTime": 0.0,
      "title": "Introduction"
    },
    {
      "startTime": 142.6,
      "title": "Ryvlin et al. (2022): Neuromodulation for Refractory Epilepsy"
    },
    {
      "startTime": 696.5,
      "title": "Ryvlin et al. (2021): Neuromodulation in epilepsy: state-of-the-art approved therapies"
    },
    {
      "startTime": 1255.2,
      "title": "Sen et al. (2021): Vagus nerve stimulation therapy in people with drug-resistant epilepsy (CORE-VNS)…"
    },
    {
      "startTime": 1883.9,
      "title": "Zhu et al. (2021): Comparison of efficiency between VNS and ANT-DBS therapy in drug-resistant epilepsy: A one…"
    },
    {
      "startTime": 2464.8,
      "title": "Doerrfuss et al. (2021): Etiology-specific response to antiseizure medication in focal epilepsy"
    },
    {
      "startTime": 3027.0,
      "title": "Final Discussion"
    }
  ]
}